Ginkgo Bioworks Holdings Inc. (DNA) stock soared 5.02% on Wednesday, likely boosted by positive news regarding its partner company Lucid Diagnostics.
Lucid Diagnostics, a commercial-stage cancer prevention medical diagnostics company, announced that its prospective clinical utility study for the EsoGuard® Esophageal DNA Test has been accepted for publication in the peer-reviewed journal Medicina.
The EsoGuard test is designed to detect esophageal precancer and cancer through early detection in at-risk patients. The clinical study demonstrated outstanding clinical utility, including an exceptionally high 85% patient compliance with referral to confirmatory upper endoscopy following EsoGuard testing in a real-world clinical setting.
Comments